Most pharmaceutical companies spend decades building brand recognition. Micro Labs achieved it almost overnight. When the COVID-19 pandemic swept across India in 2020 and 2021, one product became synonymous with fever management in a nation of 1.4 billion people: Dolo-650, a 650 mg paracetamol tablet that had been quietly on the market since 1993. The brand that made Micro Labs a household name is also the story of a family business that grew from five products and one accountant’s ambition into one of India’s most significant pharmaceutical companies.
Dolo-650 is, at its core, a simple product: 650 milligrams of paracetamol in a single tablet. There is nothing proprietary about the molecule — paracetamol is one of the most widely manufactured drugs in the world. What Micro Labs understood, long before the pandemic, was that the standard Indian paracetamol dose of 500 mg was often insufficient for high fevers, while the leap to 1,000 mg risked overdose in a market where patients frequently self-medicate. The 650 mg formulation occupied a sweet spot: more effective than standard doses, safer than the maximum.
Launched in 1993, Dolo-650 grew steadily but unremarkably for nearly three decades. Then COVID-19 arrived. As physicians across India prescribed paracetamol for fever management, Dolo-650’s reputation among doctors and pharmacists translated into extraordinary demand. Sales surged nearly 290% between the second quarters of 2020 and 2021. Production doubled. The brand became the sixth-largest pharmaceutical product in the Indian market by prescription volume and the number-one prescribed paracetamol solid oral dose in the country.
The pandemic created the brand moment, but the decades of groundwork — consistent quality, physician relationships, pharmacist trust — made it possible. A commodity molecule became a billion-rupee brand because the company had spent years earning credibility in the medical community before the crisis arrived.
The risk for any company with a dominant brand is that the brand obscures everything else. Micro Labs is far more than Dolo-650. Founded in 1973 by G.C. Surana — an accountant from Rajasthan who moved to Bangalore in search of work and ended up buying a small pharmaceutical company with five products — the company has grown into a diversified pharmaceutical manufacturer with therapeutic strengths across cardiovascular, diabetes, ophthalmology, dermatology, respiratory, and pain management.
Under the second generation — brothers Dilip and Anand Surana — Micro Labs expanded from a regional Indian company to an international operation present in more than 50 countries. The company operates 14 manufacturing plants across India, three of which hold US FDA approval (in Goa and Bangalore). These facilities produce oral solids, capsules, injectable solutions, ophthalmic preparations, and oral liquids.
Revenue has grown at a compounded annual rate of approximately 8–10% over the past five years. From roughly ₹2,491 crore in FY 2023, operating income is estimated to have reached approximately ₹6,300 crore ($759 million) in FY 2025 on a consolidated basis, with exports contributing approximately ₹920 crore. The company earned recognition as “India’s Most Technically and Scientifically Advanced Pharmaceutical Manufacturing Company of the Year 2024” at the Pharma Leaders Healthcare Super Brand Awards.
Dolo-650 may be the most visible product, but Micro Labs’ portfolio spans more than a dozen therapeutic categories. The company is a significant player in the Indian cardiovascular market, with brands in anti-hypertensives, statins, and anti-platelet agents. Its diabetes portfolio includes both oral hypoglycaemics and insulin delivery devices. In ophthalmology, Micro Labs manufactures a range of anti-glaucoma and anti-infective eye drops from its specialised facilities in Goa.
The export portfolio is increasingly important. Micro Labs has built regulatory dossiers and product registrations across 50 countries, with particular strength in Africa, Southeast Asia, the Middle East, and Latin America. The US market, served through FDA-approved manufacturing from the Goa and Bangalore facilities, represents a growing but still developing frontier for the company.
This diversification is strategic insurance. The pandemic-driven surge in Dolo-650 sales was extraordinary but unsustainable — paracetamol demand normalised as COVID-19 waned. By building depth across cardiovascular, metabolic, and ophthalmic categories, Micro Labs has ensured that its growth does not depend on any single product or any single health crisis.
Micro Labs has built a portfolio that spans from mass-market OTC brands to specialised prescription products. The company’s strength lies in identifying therapeutic niches where consistent quality and physician trust can create enduring brand value.
Micro Labs operates 14 GMP-compliant manufacturing plants across India, producing a wide range of pharmaceutical dosage forms. Three facilities — one in Goa and two in Bangalore — hold US FDA approval and are the backbone of the company’s international operations, producing oral solid tablets, capsules, injectable solutions, ophthalmic preparations, and oral liquids for regulated markets. Additional facilities carry UK MHRA accreditation.
The company’s manufacturing philosophy prioritises versatility and scale. The same plants that produce Dolo-650 in quantities measured in billions of tablets per year also manufacture specialised ophthalmic solutions and injectable products that demand entirely different quality control environments. This flexibility — the ability to shift capacity between high-volume commodity products and lower-volume speciality products — is a competitive advantage that pure-play manufacturers in either segment cannot easily replicate.
Sources: CRISIL Ratings Ltd credit reports on Micro Labs Limited (FY2023–FY2025). Micro Labs corporate disclosures and company presentations. US FDA facility registration data and Form 483 records. Indian patent office records. IPA India industry reports. Pharma Leaders Healthcare Super Brand Awards 2024.